Microarray studies reveal novel genes associated with endocrine resistance in breast cancer [Abstract]

Burmi, Rajpal Singh, McClelland, Richard Andrew, Barrow, Denise, Ellis, I. O., Robertson, J. F. R., Nicholson, Robert Ian and Gee, Julia Margaret Wendy ORCID: https://orcid.org/0000-0001-6483-2015 2006. Microarray studies reveal novel genes associated with endocrine resistance in breast cancer [Abstract]. Breast Cancer Research 8 (S2) , S11. 10.1186/bcr1554

Preview

PDF Download (296kB) | Preview

Abstract

Background Endocrine resistance is a major hurdle in breast cancer management, and determining the underlying factors driving its growth and aggressive behaviour should vastly improve treatment. Methods Microarray technology (BD Atlas Plastic Human 12 K Microarrays; GeneSifter software), verified by PCR, western blotting and immunocytochemisty, was used to identify genes increased in acquired resistant models to tamoxifen (TamR) or faslodex (FasR) as potential predictive/prognostic markers and new therapeutic targets. Results Alongside known breast cancer genes (β-catenin, PEA3, vitronectin, CD44), two novel genes in endocrine resistance were revealed (the latter never previously described in breast cancer): a securin/cell cycle regulator Pituitary Tumour Transforming Gene-1 (PTTG1), and GDNF receptor-alpha 3 (GFRα3) reported to promote cell survival signalling via RET coreceptor. Altered levels of PTTG1, GFRα3, or their associated family members were observed in further endocrine resistant states, including an additional faslodex resistant model that has progressed to a highly-aggressive state (FasR-Lt) and XMCF-7 cells resistant to oestrogen deprivation. PTTG1 and GFRα3 induction were also implicated in limiting response to anti-EGFR agents currently in breast cancer trials, with GFRα3 ligand (artemin) largely overcoming drug response. mRNA studies in clinical disease revealed PTTG1 associated with lymph node spread, high tumour grade and proliferation, while GFRα3 was enriched in ER-negative tumours and those expressing EGFR, profiles implying roles in clinical resistance and aggressive tumour behaviour. Promisingly, PTTG1 or GFRα3 siRNA knockdown promoted cell kill and inhibited proliferation in the resistant models. Conclusion Cumulatively, these data indicate PTTG1 and GFRα3 may provide useful biomarkers, and perhaps clinically relevant therapeutic targets for multiple resistant states.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Pharmacy
Subjects:	R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) R Medicine > RM Therapeutics. Pharmacology
Additional Information:	Oral Presentation. This abstract is part of the supplement: Breast cancer research: the past and the future.
Publisher:	BioMed Central
ISSN:	1465-5411
Funders:	Breast Cancer Campaign
Last Modified:	13 May 2023 19:15
URI:	https://orca.cardiff.ac.uk/id/eprint/17210

Actions (repository staff only)

Edit Item